help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH

Published ahead of print on October 4, 2007, doi:10.1164/rccm.200706-963OC

Am. J. Respir. Crit. Care Med., Volume 177, Number 1, January 2008, 66-74

A more recent version of this article appeared on January 1, 2008
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
200706-963OCv1
177/1/66    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Huang, S. K
Right arrow Articles by Peters-Golden, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huang, S. K
Right arrow Articles by Peters-Golden, M.

Submitted on June 30, 2007
Accepted on October 4, 2007

Variable Prostaglandin E2 Resistance in Fibroblasts from Patients with Usual Interstitial Pneumonia

Steven K Huang1, Scott H Wettlaufer1, Cory M Hogaboam2, Kevin R Flaherty1, Fernando J Martinez1, Jeffrey L Myers2, Thomas V Colby3, William D Travis4, Galen B Toews1, and Marc Peters-Golden1*

1 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA, 2 Department of Pathology, University of Michigan, Ann Arbor, MI, USA, 3 Department of Pathology, Mayo Clinic, Scottsdale, AZ, USA, 4 Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

* To whom correspondence should be addressed. E-mail: petersm{at}umich.edu.

Rationale: Prostaglandin (PG) E2, a cyclooxygenase-derived lipid mediator, is a potent down-regulator of fibroblast activation in normal lung fibroblasts. Although fibroblasts from patients with idiopathic pulmonary fibrosis are known to exhibit a defect in PGE2 synthesis, there is little information about their responsiveness to this lipid mediator. Objective: To compare responses to PGE2 in normal, usual interstitial pneumonia (UIP), and other diffuse parenchymal lung disease (DPLD) fibroblasts. Methods: Fibroblasts were grown in vitro from well-characterized control (n=7), UIP (n=17), or other DPLD (n=13) lung tissue. The effects of PGE2 on fibroblast proliferation and collagen expression were determined. Measurements and Main Results: Only 3 of 12 UIP fibroblast lines exhibited PGE2-mediated inhibition of both collagen synthesis and cell proliferation, as opposed to 6 of 6 non-fibrotic control cell lines. The degree of PGE2 resistance in DPLD fibroblasts was quite variable, with UIP cells exhibiting the greatest degree of resistance to PGE2 while other DPLD fibroblasts manifested a degree of resistance intermediate between control and UIP. The resistance to suppression of collagen expression correlated with worse lung function. Molecular mechanisms for resistance included altered E prostanoid receptor profiles and diminished expression of the downstream kinase, protein kinase A. Conclusion: The recognition that UIP fibroblasts manifest variable refractoriness to PGE2 suppression sheds new light on the activation phenotype of these cells and on the pathogenesis of fibrotic lung disease.


Key words: idiopathic pulmonary fibrosis, collagen, proliferation, nonspecific interstitial pneumonia, E prostanoid




This article has been cited by other articles:


Home page
Am. J. Respir. Cell Mol. Bio.Home page
S. K. Huang, S. H. Wettlaufer, J. Chung, and M. Peters-Golden
Prostaglandin E2 Inhibits Specific Lung Fibroblast Functions via Selective Actions of PKA and Epac-1
Am. J. Respir. Cell Mol. Biol., October 1, 2008; 39(4): 482 - 489.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Cell Mol. Bio.Home page
C. H. Serezani, M. N. Ballinger, D. M. Aronoff, and M. Peters-Golden
Cyclic AMP: Master Regulator of Innate Immune Cell Function
Am. J. Respir. Cell Mol. Biol., August 1, 2008; 39(2): 127 - 132.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
S. K. Huang and M. Peters-Golden
Eicosanoid Lipid Mediators in Fibrotic Lung Diseases: Ready for Prime Time?
Chest, June 1, 2008; 133(6): 1442 - 1450.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2007 American Thoracic Society